Skip to main content

Table 2 Comparison of clinical and laboratory features between SOX30 hypermethylated and non-hypermethylated MDS patients

From: Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignancies

Patient’s features

Total

(n = 104)

Non-hypermethylated

(n = 80)

Hypermethylated

(n = 24)

P value

Sex (male/female)

61/43

48/32

13/11

0.642

Median age, years (range)

62 (14–86)

63.5 (14–86)

67 (28–86)

0.689

Median WBC, ×109/L (range)

2.7 (0.6–82.4)

2.8 (0.6–82.4)

2.5 (1.1–44.4)

0.457

Median hemoglobin, g/L (range)

64 (26–140)

66 (36–140)

56 (26–107)

0.017

Median platelets, ×109/L (range)

60 (0–1176)

60 (0–754)

50 (10–1176)

0. 503

Median BM blasts, % (range)

5.0 (0.0–19.0)

5.0 (0.0–19.0)

11.0 (0.0–18.0)

0.006

WHO classifications (2018)

   

0.020

 MDS-SLD

10

9 (11%)

1 (4%)

 

 MDS-RS

7

6 (8%)

1 (4%)

 

 MDS-MLD

32

29 (36%)

3 (13%)

 

 MDS-EB1

20

16 (20%)

4 (17%)

 

 MDS-EB2

31

18 (23%)

13 (54%)

 

 MDS with isolated del(5q)

3

1 (1%)

2 (8%)

 

 MDS-U

1

1 (1%)

0 (0%)

 

IPSS scores

   

0.021

 Low

11

9 (11%)

2 (8%)

 

 Int-1

52

45 (56%)

7 (29%)

 

 Int-2

22

16 (20%)

6 (25%)

 

 High

12

5 (6%)

7 (29%)

 

No data

7

5 (6%)

2 (8%)

 

Gene mutations

    

 CEBPA (+/−)

3/91

3/71

0/20

> 0.999

 IDH1/2 (+/−)

3/91

3/71

0/20

> 0.999

 DNMT3A (+/−)

3/91

3/71

0/20

> 0.999

 U2AF1 (+/−)

6/88

1/73

5/15

0.001

 SRSF2 (+/−)

5/89

4/70

1/19

> 0.999

 SF3B1 (+/−)

6/98

4/70

2/18

0.604

  1. WBC white blood cells, BM bone marrow, IPSS International Prognostic Scoring System